Results 71 to 80 of about 13,819 (183)

Pharmacokinetics and safety of posaconazole delayed-release tablets for invasive fungal infections

Clinical Pharmacology: Advances and Applications, 2015
Nathan P Wiederhold Departments of Pathology and Medicine/Infectious Diseases, University of Texas Health Science Center at San Antonio, South Texas Reference Laboratories, San Antonio, TX, USA Abstract: Posaconazole is a broad-spectrum triazole ...
Wiederhold NP
doaj  

Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis [PDF]

, 2003
Éric Dannaoui, Jacques F. Meis, David Loebenberg, Paul E. Verweij   +3 more
openalex   +1 more source

Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazole

Infection and Drug Resistance, 2015
Ahmet SoysalDivision of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Marmara University, Istanbul, TurkeyAbstract: Posaconazole is a triazole antifungal agent that has broad-spectrum activity against many yeasts and ...
Soysal A
doaj  

Posaconazole as rescue therapy in African histoplasmosis

Brazilian Journal of Infectious Diseases
Posaconazole Histoplasmosis Salvage therapy African histoplasmosis is a granulomatous mycosis caused by Histoplasma capsulatum var. duboisii. Treatment is usually extrapolated from guidelines for classical histoplasmosis, and includes 2-4 weeks of ...
Daniel Gonçalves, Catarina Ferraz, Luisa Vaz   +2 more
doaj   +1 more source

New Drug Formulations of Posaconazole: Brief Clinical Pharmacology Review [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2016
Posaconazole is a second generation triazole with a broad spectrum of activity, which first appeared on the market in 2005 in the form of a suspension for oral administration.
Veselov A.V.
doaj  

Mutations in Aspergillus fumigatus Resulting in Reduced Susceptibility to Posaconazole Appear To Be Restricted to a Single Amino Acid in the Cytochrome P450 14α-Demethylase [PDF]

, 2003
Paul A. Mann, Raulo Parmegiani, Shui-Qing Wei, Cara Mendrick, Xin Li, David Loebenberg, Beth DiDomenico, R S Hare, Scott S. Walker, Paul M. McNicholas   +9 more
openalex   +1 more source

Mucormycosis (Zygomycosis) in a Heart-Kidney Transplant Recipient: Recovery after Posaconazole Therapy [PDF]

, 2003
Ángela María Tobón, Myrtha Arango, Darío Fernández, Ángela Restrepo   +3 more
openalex   +1 more source

Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan Parasite Trypanosoma ( Schizotrypanum ) cruzi in Immunocompetent and Immunosuppressed Murine Hosts

, 2000
Judith Molina, Olindo Assis Martins-Filho, Z. Brener, Álvaro J. Romanha, David Loebenberg, Julio A. Urbina   +5 more
openalex   +1 more source

Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects [PDF]

, 2004
Philip A. Krieter, Brian Flannery, Timothy J Musick, Mark Gohdes, Monika Martinho, Rachel Courtney   +5 more
openalex   +1 more source

Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia

, 2001
Rūta Petraitienė, Vidmantas Petraitis, Andreas H. Groll, Tin Sein, Stephen C. Piscitelli, Myrna Candelario, Aida Field‐Ridley, Nilo A. Avila, John Bacher, Thomas J. Walsh   +9 more
openalex   +1 more source